Adicet Bio (LTS:0HX7) Marketable Securities : $122.31 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Adicet Bio's Marketable Securities for the quarter that ended in Mar. 2025 was $122.31 Mil.

Adicet Bio's annual Marketable Securities stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($119.81 Mil).

Adicet Bio Marketable Securities Historical Data

The historical data trend for Adicet Bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Marketable Securities Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

10.28

119.81

Adicet Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															-	-	96.58	119.81	122.31

Adicet Bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Adicet Bio (LTS:0HX7) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Adicet Bio Marketable Securities Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany 1IJA:Germany

Address

131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Headlines

No Headlines